Figure 1. Clinical Pathway: Active Surveillance Algorithm for Patients with Early-Stage **Prostate Cancer** • T1c or T2a tumor • PSA < 10 · Gleason score 6 or less Either Conventional therapy: Active Surveillance Radiation (Class II) Surgery No Re-evaluate prostate biopsy: • Confirm less than 3 cores positive • Confirm no more than 50% of any core involved with cancer (Class III) Yes No PSA doubling-time greater than 3 years (Class II) Yes • DRE every 3 months • PSA every 3 months • Prostate biopsy at 1 year; then with PSA change or every 4-5 years (Class II) Continue AS • Change in DRE • PSA doubling time < 3 years Proceed to definitive therapy • Gleason pattern 4 or 5 on repeat No biopsy • More than 3 biopsy cores positive • More than 50% of one core positive Yes